There was no statistical evidence of a differential effect of apixaban on clinical events or bleeding in patients with or without prior HF ; however , among patients with acute HF , there were numerically fewer events with apixaban than placebo ( 14.8 vs 19.3 , HR 0.76 , 95 % CI 0.57-1 .01 , interaction P = .13 ) , a trend that was not seen in patients with prior HF or no HF .